Abstract
The continuum model of psychosis posits that psychotic symptoms are distributed throughout the population, with diagnosable clinical disorder existing at a certain point along this continuum. The total continuum is made up mainly of non-clinical cases with clinical cases of psychosis representing only a small proportion of the total extended psychosis phenotype. This paper is a narrative review of studies of psychotic experiences in the general population. The evidence indicates reasonably high prevalence rates of psychotic experiences in the general population, substantially higher than the prevalence of psychotic disorders, and that they are associated with increased risk of future onset of diagnosable disorder, particularly when the experiences are persistent. Psychotic experiences in the general population share an extensive range of risk factors with schizophrenia and therefore provide a useful phenotype in which to study the aetiology of clinical psychosis. Some types of psychotic experiences, such as paranoid ideas, bizarre thinking and perceptual abnormalities, may indicate a greater level of risk for psychotic disorder than other psychotic experiences, such as magical thinking. There is a need for research that further explores the interplay between psychotic experiences and other risk factors (including psychological, environmental, neurocognitive and genetic factors) in the evolution of psychotic disorder, the types of psychotic experiences that are most associated with risk for clinical disorder, the specificity of risk associated with psychotic experiences, and the possible adaptive advantages of these experiences.
Keywords: Psychosis, schizophrenia, risk, continuum, phenotype, schizotypy, adolescents, hallucinations, depression, PLEs
Current Pharmaceutical Design
Title: Can We Detect Psychotic-like Experiences in the General Population?
Volume: 18 Issue: 4
Author(s): B. Nelson, P. Fusar-Poli and A. R. Yung
Affiliation:
Keywords: Psychosis, schizophrenia, risk, continuum, phenotype, schizotypy, adolescents, hallucinations, depression, PLEs
Abstract: The continuum model of psychosis posits that psychotic symptoms are distributed throughout the population, with diagnosable clinical disorder existing at a certain point along this continuum. The total continuum is made up mainly of non-clinical cases with clinical cases of psychosis representing only a small proportion of the total extended psychosis phenotype. This paper is a narrative review of studies of psychotic experiences in the general population. The evidence indicates reasonably high prevalence rates of psychotic experiences in the general population, substantially higher than the prevalence of psychotic disorders, and that they are associated with increased risk of future onset of diagnosable disorder, particularly when the experiences are persistent. Psychotic experiences in the general population share an extensive range of risk factors with schizophrenia and therefore provide a useful phenotype in which to study the aetiology of clinical psychosis. Some types of psychotic experiences, such as paranoid ideas, bizarre thinking and perceptual abnormalities, may indicate a greater level of risk for psychotic disorder than other psychotic experiences, such as magical thinking. There is a need for research that further explores the interplay between psychotic experiences and other risk factors (including psychological, environmental, neurocognitive and genetic factors) in the evolution of psychotic disorder, the types of psychotic experiences that are most associated with risk for clinical disorder, the specificity of risk associated with psychotic experiences, and the possible adaptive advantages of these experiences.
Export Options
About this article
Cite this article as:
Nelson B., Fusar-Poli P. and R. Yung A., Can We Detect Psychotic-like Experiences in the General Population?, Current Pharmaceutical Design 2012; 18 (4) . https://dx.doi.org/10.2174/138161212799316136
DOI https://dx.doi.org/10.2174/138161212799316136 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
ABC Transporters in Extrahepatic Tissues: Pharmacological Regulation in Heart and Intestine
Current Medicinal Chemistry Potassium Channels in Peripheral Pain Pathways: Expression, Function and Therapeutic Potential
Current Neuropharmacology Triple Reuptake Inhibitors: The Next Generation of Antidepressants
Current Neuropharmacology Biomarker Discovery and Translation in Metabolomics
Current Metabolomics Inpatient Care of the HIV Infected Patient in the Highly Active Antiretroviral Therapy (HAART) Era
Current HIV Research Methods to Profile the Macromolecular Targets of Small Compounds
Current Topics in Medicinal Chemistry Effect of Aging on Metabolic Pathways in Endothelial Progenitor Cells
Current Pharmaceutical Design Pathological Role for Exocytotic Glutamate Release from Astrocytes in Hepatic Encephalopathy
Current Neuropharmacology Innate Immune Surveillance in the Central Nervous System Following Legionella pneumophila Infection
CNS & Neurological Disorders - Drug Targets Attention Deficit Hyperactivity Disorder and N-methyl-D-aspartate (NMDA) Dysregulation
Current Pharmaceutical Design Identification of Small Molecule as a High Affinity β2 Agonist Promiscuously Targeting Wild and Mutated (Thr164Ile) β 2 Adrenergic Receptor in the Treatment of Bronchial Asthma
Current Pharmaceutical Design Gene Therapy in the Transplantation of Allogeneic Organs and Stem Cells
Current Gene Therapy Synthesis and Biological Evaluation of Some New N4-Aryl Substituted 5-Chloroisatin-3-thiosemicarbazones
Medicinal Chemistry Cancer Chemoprevention by Targeting the Epigenome
Current Drug Targets Mechanistic Insights into Mode of Action of a Potent Natural Antagonist of Orexin Receptor-1 by Means of High Throughput Screening and Molecular Dynamics Simulations
Combinatorial Chemistry & High Throughput Screening Microcirculation in Sepsis: New Perspectives
Current Vascular Pharmacology Inflammasome as a New Therapeutic Target for Diabetic Complications
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Reacting to Stress: Radical Cellular Pathways for Novel Drug Development
Current Neurovascular Research Rosuvastatin may have Neuroprotective Effect on Spinal Cord Ischemia Reperfusion Injury
CNS & Neurological Disorders - Drug Targets Acute Oral Bryostatin-1 Administration Improves Learning Deficits in the APP/PS1 Transgenic Mouse Model of Alzheimer’s Disease
Current Alzheimer Research